At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, new late-breaking data from the CorEvitas Atopic Dermatitis (AD) Registry was presented, highlighting the real-world effectiveness of upadacitinib in treating moderate to severe AD. The data, presented by Christopher Bunick, MD, PhD, and Jonathan Silverberg, MD, PhD, MPH, among others, demonstrated significant improvements in skin clearance, itch reduction, and quality of life for both biologic-naïve and biologic-experienced patients.
Study Background
The CorEvitas AD Registry is a prospective, noninterventional registry enrolling over 4,000 adults with AD across more than 80 sites in the United States and Canada. The study evaluated 192 patients over a 6-month period, with participants categorized based on prior biologic therapy exposure. The primary endpoints included achieving a validated Investigator Global Assessment for AD (vIGA-AD) score of 0 or 1, at least a 90% improvement in the Eczema Area and Severity Index (EASI 90), and a Peak Pruritus Numeric Rating Scale (PP-NRS) score of 0 or 1.
Key Findings
Biologic-Naïve Patients: Among the 108 biologic-naïve participants, 68.5% achieved EASI 90, and 52.1% reported no or minimal itch (PP-NRS 0/1) after 6 months. Additionally, 68.7% reached minimal disease activity (MDA), defined as simultaneous achievement of EASI 90 and PP-NRS 0/1.
Biologic-Experienced Patients: In the group of 84 biologic-experienced participants, 52.6% achieved EASI 90, and 34.7% reported PP-NRS 0/1. Despite having prior exposure to biologics like dupilumab, these patients still showed substantial improvements.
The findings align with phase 3 clinical trial data, reinforcing upadacitinib’s effectiveness in routine clinical practice. The study suggests that prior biologic use does not significantly diminish upadacitinib’s therapeutic benefits, making it a versatile option for treating difficult-to-manage AD.
Future Directions
While the study provides promising insights, limitations such as the observational design and potential selection bias should be considered. Further longitudinal analyses are needed to clarify the long-term safety and durability of upadacitinib’s effects. However, these initial results highlight the drug’s potential to offer significant relief for patients with moderate to severe AD in real-world settings.
Related Topics:
